Efficacy and safety of linaclotide in treatment‐resistant chronic constipation: A multicenter, open‐label study

Abstract Background This study aimed to evaluate the efficacy and safety of linaclotide in patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS‐C) who did not respond to treatment with magnesium oxide (MgO). Method s This study was designed as a multicenter, open‐label, single‐arm, exploratory study. Patients with CC or IBS‐C who took MgO and those meeting the medication initiation criteria were administered linaclotide at a daily dosage of 500 μg for 12 weeks. The primary endpoint was a change in the Japanese version of the Patient Assessment of Constipation Quality of Life (JPAC‐QOL) score from baseline, which was evaluated by using a paired t ‐test. Key Results The patients' mean age (± standard deviation) was 67.6 ± 13.82 years. The full analysis set included 61 patients. The JPAC‐QOL total score was 1.60 at baseline and 0.70 at 12 weeks, with a significant mean change of −0.89 ± 0.721 ( p < 0.001). Several secondary endpoints also showed improvement. The frequency of spontaneous bowel movement (SBM) and complete SBM increased by 2.70 ± 7.254 ( p < 0.01) and 2.81 ± 5.254 times, respectively ( p < 0.001). The Bristol Stool Form Scale, abdominal bloating severity, and straining severity scores improved by 1.33 ± 1.274 ( p < 0.001), −0.16 ± 0.563 ( p < 0.05), and −0.46 ± 0.795 ( p < 0.001) points, respectively. The safety analysis set included 65 patients, 7 of whom had diarrhea, which improved with dose reduction and drug withdrawal. Conclusion & Inferences The study was conducted in an older adult population, similar to real clinical practice. Linaclotide may be an option for treating CC that shows an inadequate response to conventional therapy.